Followers | 144 |
Posts | 27620 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
![](https://investorshub.advfn.com/uicon/33650.png?cb=1628859195)
Tuesday, July 11, 2017 9:40:03 AM
TEL AVIV, Israel, July 11, 2017 /PRNewswire/ --
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that it has entered into definitive agreements with institutional and other investors providing for the issuance of 2,431,746 American Depositary Shares (ADS) at a purchase price of $1.45 per ADS in a registered direct offering.
Kitov will issue unregistered warrants to purchase up to 1,215,873 ADSs. The warrants will have a term of 5.5 years, be exercisable six months following the issuance date and have an exercise price of $1.50 per ADS. The offering is expected to result in gross proceeds of approximately $3,526,032
Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as the exclusive placement agent in connection with this offering.
The closing of the sale of the securities is expected to take place on or about July 14, 2017, subject to satisfaction of customary closing conditions.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM